Introduction
Left ventricular (LV) thrombi are a complication associated with anterior ST-elevation myocardial infarction, dilated cardiomyopathies, or LV aneurysms. 1 The incidence of LV thrombi has decreased in recent years with the improvement in primary reperfusion strategies, which decrease infarct size and the development of LV aneurysms. [2] [3] [4] Unlike LV thrombi, the development of right heart thrombi is often precipitated by non-infarct causes, and they are morphologically heterogeneous. Type A thrombi are mobile, serpiginous and have a
Learning points
• Right sided intracardiac thrombi should prompt the clinician to search for causes of hypercoagulability.
• T1-and T2-weighted sequences on cardiac magnetic resonance imaging may be useful to determine the age of intracardiac thrombi.
• Standard coagulation profiles do not measure the prothrom- The pulmonary artery systolic pressure was 34 mmHg, and the estimated mean right atrial pressure was 10-15 mmHg, as evidenced by an inferior vena cava (IVC) diameter of 17 mm which collapses less than 50% on inspiration. There were masses in both apices and two further masses in the right atrium suspicious for type B thrombi ( Figure 1 and Supplementary material online, Video S1). The cardiomyopathy and intracardiac masses were further analysed with cardiac magnetic resonance imaging (MRI) (Supplementary material online, Video S2), which showed the intracardiac masses had high signal intensity on T1-and T2-weighted sequences ( Figure 2 ). They were low-signal on first pass imaging following gadolinium administration. The LV and RV enddiastolic volumes were 385 mL and 305 mL, respectively. The calculated LVEF was 19% and RV ejection fraction (RVEF) 20% (Table  1) . It was likely that these derangements were due to hepatic congestion from his RV failure, as his abnormal liver enzymes and coagulation profile normalized following diuresis. The patient was started on warfarin with bridging enoxaparin, for the likely diagnosis of multiple intracardiac thrombi. Revascularization was postponed until resolution of the thrombi to avoid increased bleeding risk from triple antithrombotic therapy, due to risk of further hepatic congestion and coagulopathy. The patient was discharged home on warfarin, lisinopril 10 mg daily, frusemide 40 mg daily, and carvedilol 12.5 mg twice daily. He returned 1 month later for a follow-up MRI, which showed the LVEF was still significantly reduced at 22%, but the RVEF had improved to 46%. There was complete resolution of the all the intracardiac masses, therefore confirming the diagnosis of thrombi ( Figure 4) . Unfortunately, the patient had an aborted out of hospital cardiac arrest shortly thereafter, which led to percutaneous coronary intervention to his left anterior descending 
Discussion
Intracardiac thrombi are associated with morbidity and mortality related to embolization. Empiric anticoagulation in heart failure without other indications such as atrial fibrillation and prosthetic valves to reduce thromboembolism has been well studied. The WARCEF and COMMANDER HF trials showed no benefit for warfarin and rivaroxaban, respectively. 8,9 T1 and T2 sequences on cardiac MRI may be helpful in differentiating the age of thrombi. Different signal intensities of thrombi on cardiac MRI has been linked with the age of haemoglobin degradation, with progressive loss of T1 and T2 signals as the thrombi becomes more organized. 10 The presence of right heart thrombi, particularly in the right atrium, should prompt the clinician to search for prothrombotic conditions. These may include liver disease, sepsis, disseminated intravascular coagulation, or hereditary thrombophilia in younger patients. Liver disease is commonly associated with increased bleeding risk due to its effects on platelets and clotting factors. However, it is also associated with prothrombotic changes due to reduced production of endogenous inhibitors of coagulation such as protein C and antithrombin, while levels of factor VIII are elevated. 11 Standard coagulation tests do not measure this prothrombotic risk, though it should be appreciated by clinicians when liver disease is present. Although the intracardiac thrombi cannot be linked directly to hepatic congestion in our patient, it occurred despite the impaired coagulation system associated with hepatic dysfunction, as supported by prolonged coagulation tests. This suggests that the combination of dilated cardiomyopathy and prothrombotic changes associated with hepatic dysfunction, resulted in a hypercoagulable state, which precipitated intracardiac thrombi formation.
Supplementary material
Supplementary material is available at European Heart Journal -Case Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.
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